A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Tucatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms Triplet
- Sponsors Cascadian Therapeutics; Seattle Genetics
- 17 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Jan 2020.
- 31 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 31 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History